Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: cardiovascular disease

Upadacitinib Safety Similar to Other Jakinibs for RA

Lisa Rapaport  |  

(Reuters Health)—A once-daily 15 mg dose of upadacitinib for rheumatoid arthritis (RA) has similar rates of malignancies, serious infections, major adverse cardiovascular events, and venous thromboembolic events as other Janus kinase inhibitors (jakinibs), results from phase 3 clinical trials suggest. Researchers examined data on treatment emergent adverse events among patients taking upadacitinib in five randomized…

The Great Debate: Should Jakinibs Be Used Before Biologics after Methotrexate Failure in RA?

  |  

ACR CONVERGENCE 2020—In many ways, the current plethora of treatment options for rheumatoid arthritis patients represents an embarrassment of riches. However, while many therapeutics approved by the U.S. Food & Drug Administration (FDA) are available, knowing the order in which to try these medications with patients can be quite challenging. In The Great Debate, held…

G-Stock Studio / shutterstock.com

Conquering Systemic Racism in Medicine

Kimberly Retzlaff  |  

2020 has not only borne witness to a global pandemic, but also to increasing fervor in the fight for racial equity. In a wave of opposition to the systemic racism in the U.S., people have been in the streets demonstrating and protesting against social injustice and have taken to social media to promote political action….

Outpatient Medicine in the Post-COVID-19 Era of Telemedicine

Richard L. Allman, MD, MS, FACP, FACR  |  

Our hospitals have had their finest hour in the care of acutely ill inpatients during the COVID-19 pandemic, including dealing with allocation decisions fairly and transparently, maximizing good outcomes and remaining cognizant of the enduring ethics of healthcare. The honorable traditions of self-effacing conduct and acceptance of some level of personal risk by healthcare professionals…

Study Finds Health & Financial Benefits in AxSpA Treat-To-Target Strategy

  |  

EULAR 2020 e-CONGRESS—In what speakers at the European e-Congress of Rheumatology described as the first treat-to-target and tight control (T2T/TC) strategy trial in axial spondyloarthritis (AxSpA), researchers found such a strategy has both health and financial benefits. In the year-long study—called TICOSPA—centers were randomized to apply either a T2T/TC strategy or care left to the…

Drug Stoppages Often Feasible, but Patient Anxiety Can Be a Hurdle

  |  

Editor’s note: EULAR 2020, the annual European Congress of Rheumatology, which was originally scheduled to be held in Frankfurt, Germany, starting June 3, was moved to a virtual format due to the COVID-19 pandemic. EULAR 2020 e-CONGRESS—Although reducing medications is a reasonable option for some patients with rheumatoid arthritis (RA)—reducing cost and giving them a…

U.S. Hip Fracture Incidence Declines with Reductions in Smoking & Drinking

Lisa Rapaport  |  

(Reuters Health)—Age-adjusted hip fracture incidence has declined in the U.S. over the past four decades, aided by a decline in smoking and alcohol consumption, a new study suggests. Researchers examined data on 4,918 men and 5,634 women who participated in the prospective Framingham Heart Study from 1970 to 2010. Overall, the age-adjusted incidence of hip…

IL-1-Beta Blockade May Slow OA Progression

Reuters Staff  |  

NEW YORK (Reuters Health)—Interleukin (IL) 1 beta is a key player in the osteoarthritis (OA) inflammatory process and inhibiting it may help slow the disease process, according to an exploratory analysis of data from the CANTOS trial.1 CANTOS participants who were treated with the IL-1-beta inhibitor canakinumab had a significantly lower rate of total hip…